CD8A and neoplasm: PD-1/PD-L1 inhibitors may trigger autoimmune hepatitis (incidence: 5%–10%) via CD8+ T cell-mediated hepatotoxicity, synergizing with the tumor’s systemic inflammation to activate intrahepatic immune injury.